DK3212789T3 - Massiv parallel kombinatorisk genetik til crispr - Google Patents

Massiv parallel kombinatorisk genetik til crispr Download PDF

Info

Publication number
DK3212789T3
DK3212789T3 DK15813148.2T DK15813148T DK3212789T3 DK 3212789 T3 DK3212789 T3 DK 3212789T3 DK 15813148 T DK15813148 T DK 15813148T DK 3212789 T3 DK3212789 T3 DK 3212789T3
Authority
DK
Denmark
Prior art keywords
crispr
genetics
massive parallel
parallel combinatory
combinatory
Prior art date
Application number
DK15813148.2T
Other languages
English (en)
Inventor
Timothy Kuan-Ta Lu
Ching Gee Choi
Alan Siu Lun Wong
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of DK3212789T3 publication Critical patent/DK3212789T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
DK15813148.2T 2014-10-31 2015-10-30 Massiv parallel kombinatorisk genetik til crispr DK3212789T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073126P 2014-10-31 2014-10-31
US201562166302P 2015-05-26 2015-05-26
PCT/US2015/058304 WO2016070037A2 (en) 2014-10-31 2015-10-30 Massively parallel combinatorial genetics for crispr

Publications (1)

Publication Number Publication Date
DK3212789T3 true DK3212789T3 (da) 2020-07-27

Family

ID=54884363

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813148.2T DK3212789T3 (da) 2014-10-31 2015-10-30 Massiv parallel kombinatorisk genetik til crispr

Country Status (8)

Country Link
US (2) US20190100769A1 (da)
EP (2) EP3708155A1 (da)
JP (1) JP6788584B2 (da)
CN (1) CN107429246B (da)
DK (1) DK3212789T3 (da)
HK (1) HK1243456A1 (da)
TW (1) TWI716367B (da)
WO (1) WO2016070037A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US20150166982A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting pi3k point mutations
EP3690044B1 (en) 2014-02-11 2024-01-10 The Regents of the University of Colorado, a body corporate Crispr enabled multiplexed genome engineering
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
KR102648489B1 (ko) 2015-04-06 2024-03-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したCas9蛋白質
JP7012645B2 (ja) 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
EA201891619A1 (ru) 2016-01-11 2019-02-28 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Химерные белки и способы регулирования экспрессии генов
JP2019514377A (ja) * 2016-04-26 2019-06-06 マサチューセッツ インスティテュート オブ テクノロジー 拡張可能なリコンビナーゼカスケード
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
CN109688820B (zh) 2016-06-24 2023-01-10 科罗拉多州立大学董事会(法人团体) 用于生成条形码化组合文库的方法
US11913017B2 (en) * 2016-06-29 2024-02-27 The Regents Of The University Of California Efficient genetic screening method
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
EP3510152A4 (en) * 2016-09-07 2020-04-29 Flagship Pioneering, Inc. METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US20190330616A1 (en) * 2016-12-29 2019-10-31 Johann Wolfgang Goethe-Universität Frankfurt am Main Method for generating higher order genome editing libraries
EP3565891B1 (en) 2017-01-09 2023-04-12 Whitehead Institute for Biomedical Research Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
WO2018145041A1 (en) * 2017-02-06 2018-08-09 10X Genomics, Inc. Systems and methods for nucleic acid preparation
US10995333B2 (en) 2017-02-06 2021-05-04 10X Genomics, Inc. Systems and methods for nucleic acid preparation
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
MX2020001178A (es) 2017-07-31 2020-09-25 Regeneron Pharma Celulas madre embrionarias de raton transgenico con cas y ratones y usos de los mismos.
JP2020533957A (ja) 2017-07-31 2020-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Crisprリポーター非ヒト動物およびその使用
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof
EP3853363A4 (en) * 2018-09-19 2022-12-14 The University of Hong Kong ENHANCED HIGH THROUGHPUT COMBINATORY GENE MODIFICATION SYSTEM AND OPTIMIZED CAS9 ENZYME VARIANTS
CN113646434B (zh) * 2018-12-20 2023-05-30 北京大学 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
CN110652589A (zh) * 2019-10-12 2020-01-07 中国人民解放军陆军军医大学 Gasc1抑制剂在制备治疗肝癌的药物中的应用
US20230002756A1 (en) * 2019-12-12 2023-01-05 The Trustees Of The University Of Pennsylvania High Performance Platform for Combinatorial Genetic Screening
EP4136238A1 (en) * 2020-04-16 2023-02-22 The University of Hong Kong A system for three-way combinatorial crispr screens for analysing target interactions and methods thereof
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
WO2022159402A1 (en) * 2021-01-19 2022-07-28 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for high-multiplexed genome engineering using synthetic crispr arrays
WO2022195582A1 (en) * 2021-03-15 2022-09-22 G.T.A.I Innovation Ltd. A method and apparatus for lab tests
CN113599522B (zh) * 2021-08-03 2022-09-20 深圳市北科生物科技有限公司 Kdm6作为靶标在制备用于提高早期神经外胚层分化效率的药物中的应用
AU2022343300A1 (en) 2021-09-10 2024-04-18 Agilent Technologies, Inc. Guide rnas with chemical modification for prime editing
CN116019811B (zh) * 2023-02-07 2024-04-12 华中科技大学协和深圳医院 Gsk-j4用于制备抗革兰氏阳性菌感染药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005108568A1 (en) * 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
WO2011143660A2 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
EA038924B1 (ru) 2012-05-25 2021-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции рнк-специфической модификации днк-мишени и рнк-специфической модуляции транскрипции
CN103516916B (zh) 2012-06-28 2018-03-27 中兴通讯股份有限公司 拨号方法及装置
CA2877962C (en) * 2012-06-29 2018-06-05 Massachusetts Institute Of Technology Massively parallel combinatorial genetics
MD20150043A2 (ro) * 2012-10-02 2015-08-31 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
US9073878B2 (en) * 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
CN103833671B (zh) * 2012-11-27 2016-12-21 中国科学院上海药物研究所 一类二氢噻唑酮类化合物及其药物组合物和用途
KR102531576B1 (ko) * 2012-12-06 2023-05-11 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
ES2883590T3 (es) * 2012-12-12 2021-12-09 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas
US20140310830A1 (en) * 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014235794A1 (en) * 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
JP6370368B2 (ja) 2013-03-27 2018-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Brd4阻害剤としてのインドリノン類似体
RU2725502C2 (ru) * 2013-06-17 2020-07-02 Те Брод Инститьют Инк. Доставка, конструирование и оптимизация систем, способы и композиции для целенаправленного воздействия и моделирования заболеваний и нарушений постмитотических клеток
MX2016007327A (es) * 2013-12-12 2017-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para dirigirlos a trastornos y enfermedades usando componentes para suministro de particulas.
AU2014361781B2 (en) * 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
BR112016013207A2 (pt) * 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
US20170022499A1 (en) * 2014-04-03 2017-01-26 Massachusetts Institute Of Techology Methods and compositions for the production of guide rna
EP3137079A1 (en) * 2014-04-28 2017-03-08 The J. David Gladstone Institutes Inhibitors of jmjd2c as anticancer agents
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
WO2016049024A2 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo

Also Published As

Publication number Publication date
EP3212789A2 (en) 2017-09-06
WO2016070037A8 (en) 2017-03-02
US20210310022A1 (en) 2021-10-07
CN107429246A (zh) 2017-12-01
JP6788584B2 (ja) 2020-11-25
WO2016070037A2 (en) 2016-05-06
WO2016070037A3 (en) 2016-06-23
TW201631155A (zh) 2016-09-01
TWI716367B (zh) 2021-01-21
EP3708155A1 (en) 2020-09-16
EP3212789B1 (en) 2020-04-22
US20190100769A1 (en) 2019-04-04
CN107429246B (zh) 2021-06-01
JP2017534285A (ja) 2017-11-24
HK1243456A1 (zh) 2018-07-13

Similar Documents

Publication Publication Date Title
DK3212789T3 (da) Massiv parallel kombinatorisk genetik til crispr
CU20160125A7 (es) Inhibidores de diacilglicerol aciltransferasa 2
LT3102748T (lt) Dengiančios grotelės
FR3028872B1 (fr) Procede de fractionnement
DK3125898T3 (da) Farmakofor til trail-induktion
DK3161247T3 (da) Brøndsystem
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3230929T3 (da) Forbedringer til tælleranordninger
UA31197S (uk) Таблетка
BR112016026476A2 (pt) Bloco de corrente
PT3151658T (pt) Ferradura
DK3104758T3 (da) Udtagskassesystem til centralstøvsugersystem
BR112017001926A2 (pt) processamento de eletrofluido
DK3399096T3 (da) Vandmærkedannelse
RS55759B1 (sr) Rešetka za industrijsku termičku obradu
ES1119860Y (es) Caramelo
ES1100207Y (es) Válvula de alimentación
ITUB20159518A1 (it) Paratia antiallagamento
DK3167215T3 (da) Implementeringssystem til glidemagnetventiler
TH1601002609A (th) กระบวนการทำอะดามันทานาไมด์
CL2015000667S1 (es) Machacadora.
FI20140262A (fi) Erikois mutteriavain
GB201410071D0 (en) Database processing
ES1210093Y (es) Arbol de agitador de un fermentador
GB201403921D0 (en) Improved database